Medtronic received information via literature regarding a comparison of the mid-term clinical and hemodynamic outcomes in patients who underwent full aortic root replacement with the biointegral composite biological valve or the stentless freestyle bioprosthesis.All data were prospectively collected from a single center between february 2013 and july 2017.The study population included 267 patients and was predominantly male with a mean age of 67 years and a mean weight of 74 kg.Of those, 65 were implanted with medtronic freestyle bioprosthetic valves.No serial numbers were provided.Among all freestyle patients, 27 deaths occurred within a mean follow-up period of 31 months.No further details were provided.Based on the available information, medtronic product was not directly associated with the deaths.Among all freestyle patients, intra-operative and post-operative adverse events included: permanent pacemaker implantation due to co mplete/permanent atrioventricular block, reoperation due to valve-related causes, reoperation due to unspecified causes, coronary artery bypass grafting due to coronary ostial misplacement, extracorporeal membrane oxygenation or intra-aortic balloon pump support, stroke, major bleeding, tracheostomy, pericardial effusion, new-onset atrial fibrillation, wound infection, myocardial infarction, valve-related endocarditis, and decreased ejection fraction.Based on the available information, medtronic product may have been associated with the adverse events.No additional adverse patient effects or product performance issues were reported.
|